This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
rsi: Archive
After Plunging -22.28% in 4 Weeks, Here's Why the Trend Might Reverse for Zevia (ZVIA)
by Zacks Equity Research
Zevia (ZVIA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ZVIANo Net Change
rsi stock-price-movement
Down -10.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Chewy (CHWY)
by Zacks Equity Research
Chewy (CHWY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CHWYPositive Net Change
rsi stock-price-movement
Down -22.39% in 4 Weeks, Here's Why NextDecade (NEXT) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for NextDecade (NEXT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
NEXTNo Net Change
rsi stock-price-movement
Down -12.63% in 4 Weeks, Here's Why You Should You Buy the Dip in TG Therapeutics (TGTX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for TG Therapeutics (TGTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TGTXPositive Net Change
rsi stock-price-movement
Down -16.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Yext (YEXT)
by Zacks Equity Research
Yext (YEXT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
YEXTPositive Net Change
rsi stock-price-movement
Down -10.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Cerence (CRNC)
by Zacks Equity Research
Cerence (CRNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CRNCPositive Net Change
rsi stock-price-movement
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in SunOpta (STKL)
by Zacks Equity Research
SunOpta (STKL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
STKLNo Net Change
rsi stock-price-movement
Down -41.23% in 4 Weeks, Here's Why Apellis Pharmaceuticals, Inc. (APLS) Looks Ripe for a Turnaround
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
APLSNegative Net Change
rsi stock-price-movement
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SCPHNegative Net Change
rsi stock-price-movement
After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
THRXPositive Net Change
rsi stock-price-movement
After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ADCTPositive Net Change
rsi stock-price-movement
After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
RVNCPositive Net Change
rsi stock-price-movement
Here's Why Boston Beer (SAM) is Poised for a Turnaround After Losing -9.92% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Boston Beer (SAM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SAMNegative Net Change
rsi stock-price-movement
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
KURAPositive Net Change
rsi stock-price-movement
Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FGENPositive Net Change
rsi stock-price-movement
Down -32.11% in 4 Weeks, Here's Why You Should You Buy the Dip in Stereotaxis Inc. (STXS)
by Zacks Equity Research
Stereotaxis Inc. (STXS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
STXSNegative Net Change
rsi stock-price-movement
Down -13.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Humana (HUM)
by Zacks Equity Research
Humana (HUM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
HUMPositive Net Change
rsi stock-price-movement
Down -31.17% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
by Zacks Equity Research
Aquestive Therapeutics (AQST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AQSTNegative Net Change
rsi stock-price-movement
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
by Zacks Equity Research
Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
NKTXNegative Net Change
rsi stock-price-movement
Down -9.12% in 4 Weeks, Here's Why You Should You Buy the Dip in Reservoir Media, Inc. (RSVR)
by Zacks Equity Research
Reservoir Media, Inc. (RSVR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
RSVRPositive Net Change
rsi stock-price-movement
After Plunging -19.71% in 4 Weeks, Here's Why the Trend Might Reverse for PagerDuty (PD)
by Zacks Equity Research
PagerDuty (PD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
PDNegative Net Change
rsi stock-price-movement
Down -7.74% in 4 Weeks, Here's Why Royal Gold (RGLD) Looks Ripe for a Turnaround
by Zacks Equity Research
Royal Gold (RGLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RGLDNegative Net Change
rsi stock-price-movement
Maxeon Solar Technologies, Ltd. (MAXN) Loses -10.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Maxeon Solar Technologies, Ltd. (MAXN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MAXNNegative Net Change
rsi stock-price-movement
After Plunging -17% in 4 Weeks, Here's Why the Trend Might Reverse for Silvercorp (SVM)
by Zacks Equity Research
Silvercorp (SVM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SVMNegative Net Change
rsi stock-price-movement
Down -7.81% in 4 Weeks, Here's Why Clorox (CLX) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Clorox (CLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CLXNegative Net Change
rsi stock-price-movement